ONCAlert | 2018 ASCO Annual Meeting
News  >  

Edward Wolin to Direct Neuroendocrine Center at Tisch Cancer Institute

Danielle Ternyila
Published Online:1:01 PM, Wed March 14, 2018

Edward M. Wolin, MD
Edward M. Wolin, MD, has been named the director of the Center for Carcinoid and Neuroendocrine Tumors at The Tisch Cancer Institute of Mount Sinai Health System. He will also serve as a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai.

Wolin will bring a research program of clinical trials aimed at the discovery of effective treatments for patients with carcinoid and neuroendocrine tumors (NETs), including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging. He will lead the center with associate director, Michelle Kang Kim, MD, PhD, associate professor of medicine (gastroenterology), who served as interim director. She is known for her work in translational and epidemiologic approaches to assessing patient outcomes.

“We are very excited about Dr Wolin joining The Tisch Cancer Institute. With his remarkable expertise and research experience, Dr Wolin will lead Mount Sinai’s program to a new level of prominence,” William K. Oh, MD, associate director for clinical and translational research and deputy director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, said in a statement.

Previously, Wolin served as the director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care. His research has pioneered the way for novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy in the treatment of patients with NETs.

Wolin has held other leadership positions in his past, including at the University of Kentucky Medical Center, Cedars-Sinai Medical Center in Los Angeles, Carcinoid Cancer Foundation, and the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. Previously he was a clinical fellow at the National Cancer Institute of the National Institutes of Health. He is also a reviewer for various journals, such as the Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.

Richard P. Warner, MD, founded this multidisciplinary center, which brings together many different specialists, as a pioneer in NET research and treatment. Wolin succeeds Warner’s position as the second director of the center.

“My goal is to continue to build upon the groundwork laid by Dr Warner who devoted his life’s work to investigating these rare tumors,” Wolin said in a statement. “He created a multidisciplinary approach to treatment, and trained other physicians such as myself. We have tremendous surgeons, gastroenterologists, radiologists, nuclear medicine doctors, cardiologists, and other specialists who all work together to treat these complex cancers.”

“As a medical oncologist specializing in these tumors, I will bring new therapies and coordinate care to help bring the program to the next level,” he added.

The team at Mount Sinai Health Systems is excited to welcome Wolin onboard, according to a press release from the organization. His extraordinary experience and expertise in tumors is expected to make a huge impact on the program.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.